The treatment of newly diagnosed acute lymphocytic leukemia (ALL) in adults remains unsatisfactory. Not withstanding the outstanding progress in curing childhood ALL, only approximately one third of adults younger than 60 years can be cured, and the overall published survival curves have not changed significantly during the past 15 years. Recent therapeutic advances in allogeneic transplantation through the conduct of large collaborative studies, better understanding of the relevance of cytogenetics, improved molecular techniques for the detection of minimal residual disease, and clinical research into novel biologic and targeted therapies have all combined to offer potentially a better hope for an improved outcome in this disease. The current approach in 2007 to the management of this disease is presented by way of a discussion of illustrative cases. In this uncommon and difficult disease, well-structured intergroup studies will remain vital for future progress.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2007-05-038950 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful Resolution of Suspected Red Yeast Rice-induced Nephropathy.
Intern Med
March 2025
Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Japan.
Recently, several Japanese patients have developed interstitial nephritis or acute tubular injury/necrosis, both accompanied by Fanconi syndrome, after consuming a specific red yeast rice supplement. In most cases, the renal function did not fully recover even after discontinuation of supplements and glucocorticoid treatment. A 52-year-old woman developed interstitial nephritis and Fanconi syndrome after receiving supplements.
View Article and Find Full Text PDFTalicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Lancet Haematol
March 2025
Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India. Electronic address:
Background: In low-income and middle-income counties (LMICs), the outcome of relapsed or refractory B-cell malignancies is poor due to the absence of effective therapies. We report the results of a phase 1/2 study of a novel humanised anti-CD19 4-1BB chimeric antigen receptor (CAR) T-cell therapy, talicabtagene autoleucel, for patients with relapsed or refractory B-cell malignancies.
Methods: This open-label, multicentre, phase 1/2 study was done at six tertiary cancer centres in India.
Risk prediction and early intervention strategies for persistent SARS-CoV-2 infection in patients with non-Hodgkin lymphoma: a retrospective cohort study.
BMC Pulm Med
March 2025
Department of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Background: Patients with non-Hodgkin lymphoma (NHL) face heightened mortality and accelerated disease progression when persistently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This critical situation underscores the urgent need to identify risk factors and establish early intervention strategies tailored to this vulnerable population. The primary aim of this study was to investigate the risk factors associated with persistent SARS-CoV-2 infection in NHL patients during the COVID-19 pandemic.
View Article and Find Full Text PDFMarkers of inflammation predicts long-term mortality in patients with acute coronary syndrome - a cohort study.
BMC Cardiovasc Disord
March 2025
School of Public Health and Community Medicine/Primary Health Care, University of Gothenburg, Göteborg, Sweden.
Background: Chronic low-grade inflammation is a well-known risk factor for coronary heart disease (CHD) and future cardiovascular events. Anti-inflammatory therapy can reduce the risk of ischemic cardiovascular disease (CVD) events following myocardial infarction (MI). However, it remains unknown to what extent inflammation at the time of an acute event predicts long-term outcomes.
View Article and Find Full Text PDFCase report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia.
Ann Hematol
March 2025
The Department of Hematology, Affiliated Dongyang Hospital of Wenzhou Medical University, 60 West Wuning Road, Dongyang, 322100, Zhejiang, China.
Introduction: Mature plasmacytoid dendritic cell proliferation (MPDCP) is generally considered to be associated with myeloid neoplasms. To date, case reports of MPDCP associated with lymphoid malignancies are exceedingly rare.
Case Report: Herein, we report the case of a 69-year-old male who presented with multiple enlarged preauricular, cervical, inguinal, and axillary lymph nodes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!